Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

241 results about "Surgical resection" patented technology

Colon Resection Colon resection, also known as colectomy is a surgical method of removing a part or the whole of the large intestine. The colon is constituted of ascending, transverse, descending, and sigmoid colon, and the rectum. Resection of the colon is a surgical procedure carried out to remove a part or the whole of an infected colon.

Kilovoltage delivery system for radiation therapy

A small tabletop stationary five-degree of freedom device such as a “robot” is used to define the treatment region by tracing the region under direct visualization and then to precisely deliver the treatment plan created by an automatic planning system by positioning a single low energy radiation source, or a plurality of low energy sources connected to each other in a predetermined parallel or similar geometry, each source equipped with blocking and attenuation mechanisms, at a plurality of positions in a planar fashion across or through a selected treatment field, thereby delivering a plurality of parallel overlapping beams indexed on a millimeter or submillimeter grid such that a concentration of dose is achieved at a variable depth in tissue relative to the dose where the radiation first enters the tissue and can be used to treat regions on or below the surface of tissue, in a cavity and underlying region created following a surgical resection, on or below the surface of an internal cavity, hollow viscus, or lumen, or deep in tissue adjacent to an inserted probe or conduit or catheter. By generating a plurality of overlapping beams indexed on a millimeter or submillimeter grid that converge on a target volume loaded with gold nanoparticles, a tumorcidal dose of radiation can be delivered in as little as a single session to tumor cells but not to normal cells within or outside the treatment volume. This approach also makes it possible to deliver serial radiosurgical treatments.
Owner:CAROL MARK PHILIP

Prognostic signature for oral squamous cell carcinoma

The present disclosure describes methods and compositions for diagnosing or predicting likelihood of a OSCC recurrence in a subject having undergone OSCC resection comprising: a) determining an expression level of one or more biomarkers selected from Table 4, 5 and / or 7, optionally MMP1, COL4A1, THBS2 and / or P4HA2 in a test sample from the subject, the one or more biomarkers comprising at least one of THBS2 and P4HA2, and b) comparing the expression level of the one or more biomarkers with a control, wherein a difference or a similarity in the expression level of the one or more biomarkers between the test sample and the control is used to diagnose or predict the likelihood of OSCC recurrence in the subject In particular, the present disclosure describes methods and compositions using a four-gene biomarker signature that can predict recurrence of oral squamous cell carcinoma in subjects that have histologically normal surgical resection margins.
Owner:UNIV HEALTH NETWORK

Temporary tissue spacer and pretreatment balloon

A device for preventing closure of a surgically created resection cavity within tissues of the body comprises an insertion member having a distal end for insertion into a surgically created resection cavity and a proximal end which remains outside the resection cavity and a lumen extending between the proximal and distal ends and an inflatable member deployable from the distal end of the insertion member, an inner chamber of the inflatable member being fluidly coupled to the lumen to receive an inflation fluid therefrom so that, when the inflation fluid is supplied to the inflatable member, the inflatable member expands so that an outer surface of the inflatable member contacts the surrounding tissue and moves the surrounding tissue out of the resection cavity. A method of treating tissue surrounding a surgically created resection cavity, comprises the steps of, after a portion of tissue has been surgically removed to create a resection cavity, inserting a distal end of a catheter into the resection cavity and deploying an inflatable element at a desired location within the resection cavity from a distal portion of the catheter in combination with the steps of inflating the inflatable element to contact inner surfaces of the resection cavity and maintain tissue surrounding the resection cavity in a position substantially corresponding to a position of the tissue prior to the creation of the resection cavity to prevent closure of the resection cavity by healing processes during a recovery period and, after the recovery period, treating the tissue surrounding the resection cavity.
Owner:BOSTON SCI SCIMED INC

Interferon immunotherapy

A method for reducing the recurrence of a resectable malignant tumor includes administering an immunostimulatory dosage of an α-interferon composition, then surgically resecting the malignant tumor. A method for treating a human patient having a non-resectable malignant tumor includes administering an immunostimulatory dosage of an α-interferon composition to the patient and treating the patient with effective non-surgical medical methodologies to diminish the tumor. An article of manufacture combines an α-interferon composition within a packaging material and a package label or insert indicating that administration of an immunostimulatory dosage of an α-interferon composition followed by surgical resection of a malignant tumor can be effective for treating a human patient having the malignant tumor.
Owner:MAYO FOUND FOR MEDICAL EDUCATION & RES

Bibw 2992 for use in the treatment of triple negative breast cancer

The present invention relates to a method of treating patients suffering from triple negative breast cancer comprising administration of an effective amount of the irreversible EGFR / HER1 and HER2 inhibitor BIBW 2992 (1) to a person in need of such treatment, optionally in combination with the administration of a further chemotherapeutic agent (2), in combination with radiotherapy, radio-immunotherapy and / or tumour resection by surgery.
Owner:BOEHRINGER INGELHEIM INT GMBH

Radionuclide-labelled biodegradable bioabsorbable biopolymer nano fibrous membrane, preparation process and application thereof

The invention relates to a radionuclide-labelled biodegradable bioabsorbable biopolymer nano fibrous membrane, a preparation process and application thereof. The preparation process includes steps of firstly adopting the electrostatic spinning technique to prepare a biopolymer nano fibrous membrane consisting of biopolymer nano fibers with diameters ranging from 50nm to 5000nm, performing chemical modification on the surface of the biopolymer nano fibrous membrane, enabling the surface of the biopolymer nano fibrous membrane to be in coupling reaction with double-functional-group coupling agent, chelating the surface of the biopolymer nano fibrous membrane after coupling reaction in buffer solution of acetic acid-sodium acetate anhydrous containing radionuclide compounds, and finally obtaining the radionuclide-labelled biodegradable bioabsorbable biopolymer nano fibrous membrane, wherein the double-functional-group coupling agent which is combined with amino in biopolymer nano fibers via chemical bonds on the surface of the biopolymer nano fibrous membrane, the radionuclide is chelated and fixed on the surface of the biopolymer nano fibrous surface via the double-functional-group coupling agent. The radionuclide-labelled biodegradable bioabsorbable biopolymer nano fibrous membrane can be used as an oncotherapy material or a material for focal tissue portions after tumor resection operation.
Owner:INST OF CHEM CHINESE ACAD OF SCI +1

Anticancer sustained-release gel injection containing taxone medicine

A sustained-release gel injection comprises sustained-release microspheres containing taxanes drug, amphiphilic block copolymer, solvent and release regulator, wherein the mixture of the amphiphilic block copolymer and the solvent has a temperature sensitive gelatinization characteristic, and can automatically become non-flowing degradable water insoluble gel, which can locally and slowly release drug at tumor foci for several weeks to several months, after injection into body. The preparation can be injected into or around a tumor for treating solid tumors at different stages. The preparation has the effects of controlling residual tumor cells relapsed after operation and tumors that can not be excised via operation, controlling complications at late stage of tumors, and enhancing treatment effect of chemotherapy and radiotherapy (particularly radioactive particles). The taxanes are selected from docetaxel, taxol, epitaxol, hydroxyl taxol and deacetyltaxol; the amphiphilic block copolymer is PLGA-PEG-PLGA copolymer, wherein the PEG has molecular weight of 1200-1600, accounting for 20 wt% of the amphiphilic block copolymer; and in the glycolide-lactide copolymer, the mol ratio of glycolide and lactide is 6:1.
Owner:济南基福医药科技有限公司

Delivery system for radiation therapy

A small tabletop stationary five-degree of freedom device such as a “robot” is used to define the treatment region by tracing the region under direct visualization and then to precisely deliver the treatment plan created by an automatic planning system by positioning a single low energy radiation source, or a plurality of low energy sources connected to each other in a predetermined parallel or similar geometry, each source equipped with blocking and attenuation mechanisms, at a plurality of positions in a planar fashion across or through a selected treatment field, thereby delivering a plurality of parallel overlapping beams indexed on a millimeter or submillimeter grid such that a concentration of dose is achieved at a variable depth in tissue relative to the dose where the radiation first enters the tissue and can be used to treat regions on or below the surface of tissue, in a cavity and underlying region created following a surgical resection, on or below the surface of an internal cavity, hollow viscus, or lumen, or deep in tissue adjacent to an inserted probe or conduit or catheter. By generating a plurality of overlapping beams indexed on a millimeter or submillimeter grid that converge on a target volume loaded with gold nanoparticles, a tumorcidal dose of radiation can be delivered in as little as a single session to tumor cells but not to normal cells within or outside the treatment volume. This approach also makes it possible to deliver serial radiosurgical treatments.
Owner:TRIPLE RING TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products